Last reviewed · How we verify
TURALIO™
Turalio works by inhibiting a specific biological pathway.
Turalio is a small molecule drug developed by Daiichi Sankyo, but its target, drug class, and approved indications are unknown. As a small molecule, it is a type of medication that can be taken orally and is designed to interact with specific biological pathways. The commercial status of Turalio is unclear, and it is not known whether it is patented or has generic manufacturers. Further information on its safety considerations and pharmacological properties is also unavailable. As a result, Turalio remains a relatively unknown entity in the pharmaceutical industry.
At a glance
| Generic name | TURALIO™ |
|---|---|
| Sponsor | Daiichi Sankyo |
| Target | AP2-associated protein kinase 1, Aurora kinase B, Cyclin-dependent kinase 19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like a city with many roads and intersections. Turalio is like a traffic cop that helps regulate the flow of traffic by blocking certain roads, which can help slow down the growth of abnormal cells. This can be beneficial in treating certain diseases, but more research is needed to understand its full effects.
Approved indications
- Tenosynovial giant cell tumor
Common side effects
- Increased lactate dehydrogenase
- Increased aspartate aminotransferase
- Hair color changes
- Fatigue
- Increased alanine aminotransferase
- Decreased neutrophils
- Increased cholesterol
- Increased alkaline phosphatase
- Decreased lymphocytes
- Eye edema
- Decreased hemoglobin
- Rash
Serious adverse events
- Abnormal liver tests
- Hepatotoxicity
- Increased ALT
- Increased AST
- Increased bilirubin
- Increased GGT
- Cholangitis
- Liver disorder
- Cognitive disorders
- Photosensitivity reactions
Key clinical trials
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan (PHASE2)
- A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
- A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |